<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335020">
  <stage>Registered</stage>
  <submitdate>14/01/2010</submitdate>
  <approvaldate>19/01/2010</approvaldate>
  <actrnumber>ACTRN12610000055000</actrnumber>
  <trial_identification>
    <studytitle>Assessment of sensitivity and therapeutic response to next-line therapy in Chronic Myeloid Leukaemia (CML)</studytitle>
    <scientifictitle>Response Post Tyrosine Kinase Inhibitor: Assesment of sensitivity and therapeutic response to next-line therapy in Chronic Myeloid Leukaemia (CML).</scientifictitle>
    <utrn />
    <trialacronym>CML10 RESIST</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Myeloid Leukaemia (CML)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This an observational study, collecting data at regular intervals (6monthly) on subjects for five years. Observing current treatment, change in treatment and rationale for change</interventions>
    <comparator>there is no treatment intervention prescribed, patient therapy is at the discretion of the treating physician and as such data collection on when patients cease or change therapy is being collected.</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>the range and frequency of next-line therapies. The clincian will complete data into the case report form and submit to trial coordinating centre.</outcome>
      <timepoint>6month data collection.
 12month data review annually for five years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>progression free survival by routine blood tests performed as standard by the clinician</outcome>
      <timepoint>3 or 6 monthly depending on patient and clinician. it is an observational study, so these timepoints may change according to the treating clinician and patient.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>overall survival, measured at visit to clinician.</outcome>
      <timepoint>at each clinician visit, 6monthly minimum.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients of any age
Currently recieving Tyrosine Kinase Inhibitor(TKI) 
Patients with Philadelphia Positive or Breakpoint Cluster Region (BCR) V-abl Abelson murine leukaemia viral oncogene homolog1 (ABL) confirmed CML.
Patients in any phase of CML including those with relapsed CML following allogeneic stem cell transplantation
Patients who can provide written informed consent. Minors must have parental/legal guardian consent and assent where required</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>If in the investigator's opinion the patient is unlikely candidate for follow-up information due to unavailability.
Previous enrolment to the same registry.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/02/2010</anticipatedstartdate>
    <actualstartdate>8/06/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>30/11/2015</actualenddate>
    <samplesize>1000</samplesize>
    <actualsamplesize>679</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Leukaemia and Lymphoma Group (ALLG)</primarysponsorname>
    <primarysponsoraddress>Level 2, 10 St Andrews Place
East Melbourne
Victoria 3002</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>BristolMyersSquibb</fundingname>
      <fundingaddress>BMS Pharmaceuticals Australia
PO Box 39 
NOBLE PARK NORTH, VICTORIA 3174</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis</fundingname>
      <fundingaddress>Novartis Pharmaceuticals Australia
54 Waterloo Road
North Ryde NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress>nil</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The target population for this study includes CML patients of any age residing in Australia or New Zealand with CML who have stopped TKI for any reason. Patients will be observed by there regular clinician and data submitted to the central trial coordinating centre.</summary>
    <trialwebsite />
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate>27/05/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/02/2010</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Timothy Hughes</name>
      <address>Principal Investigator CML10
South Australia Pathology
Frome Road
Adelaide
South Australia 5000</address>
      <phone>61882223330</phone>
      <fax>61882223737</fax>
      <email>not available</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bronwen Cox</name>
      <address>CML10 Trial Coordinator
Level 3 East Wing
Royal Adelaide Hospital 
North Terrace
Adelaide South Australia 5000</address>
      <phone>61882223375</phone>
      <fax>61882223368</fax>
      <email>bronwen.cox@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Delaine Smith</name>
      <address>Level2, 10 St Andrews Place
East Melbourne
3002
Victoria</address>
      <phone>610396563656</phone>
      <fax>610396561420</fax>
      <email>delaine.smith@petermac.org</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>